G
GLP1 Lawsuit
Mass Tort Case Review
Call
GLP-1 Drug Injury

Semaglutide Lawsuit

Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus — all sold by Novo Nordisk. Thousands of users are filing claims for severe gastrointestinal, optic, and other injuries.

Call (717) 724-7503

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.

Why semaglutide is at the center of MDL 3094

Semaglutide was the first widely prescribed GLP-1 weight-loss therapy. Its rapid adoption is now matched by a rapidly growing docket of injury claims, all consolidated in the Eastern District of Pennsylvania.

Qualifying injuries

Gastroparesis, severe pancreatitis, intestinal obstruction, gallbladder disease, vision loss (NAION), and aspiration pneumonia are the principal claims. New injury categories continue to be added as evidence develops.

Frequently Asked Questions

Get your free, confidential case review

Takes under 60 seconds. No fee unless you win.

Free Confidential Case Review

No fee unless you win. Takes under 60 seconds.